NCT01782313: A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas |
|
|
| Completed | 2 | 58 | US | tivozanib, AV-951, oral VEGF receptor tyrosine kinase inhibitor AV-951, laboratory biomarker analysis | Northwestern University, AVEO Pharmaceuticals, Inc. | Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma | 05/15 | 12/16 | | |
| Recruiting | 1/2 | 29 | US | Atezolizumab, Tecentriq, Tivozanib, Fotivda | University of Florida, Genentech, Inc., Aveo Oncology Pharmaceuticals | Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer | 12/24 | 12/25 | | |